Chuanbing Huang

Dr. Chuanbing Huang

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 June 2025 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JCJunjie Chen
Junjie Chen
XCXianshuai Chen
Xianshuai Chen
TWTianshu Wang
Tianshu Wang
MLMing Li
Ming Li
HDHuanhuan Dai
Huanhuan Dai
CHChuanbing Huang
Chuanbing Huang
Introduction: To present the global, regional, and national burden of knee osteoarthritis (KOA) and its causative factors, categorized by age, gender, and sociodemographic indices from 1990 to 2021, and to project future trends to 2035. Methods: A comprehensive analysis of KOA epidemiology was conducted using data from the 2021 Global Burden of Disease Study (GBD). The study examined change trends in KOA burden between 1990 and 2021, including prevalence, incidence, disability-adjusted life years (DALYs), and associated risk factors. Health inequality analyses were performed using slope index of inequality (SII) and concentration index (CI). Decomposition analysis was conducted to understand the contributions of population growth, aging, and epidemiological changes to the increasing burden. Future projections were made for global, Chinese, and Indian trends to 2035. Results: In 2021, the global prevalence of KOA was 374.7 million cases, with an annual incidence of 3.0846 million cases, totaling 12.01 million DALYs. Age-standardized rates for prevalence, incidence, and DALYs increased by 8.3%, 7.1%, and 8.2% respectively since 1990. Health inequality analyses revealed widening disparities across SDI levels, with SII for crude incidence rates increasing from 251 to 400 per 100,000 between 1990 and 2021. Decomposition analysis showed population growth as the primary driver of increased burden globally (75.07% for DALYs), with variations across SDI regions. Projections to 2035 indicate substantial increases in global burden, with incidence expected to rise by 33.6%, prevalence by 43.8%, and DALYs by 41.4%. China and India show differing patterns in projected burden increases. Conclusion: KOA remains a significant public health concern with increasing burden and widening health inequalities. The projected increases highlight the need for targeted interventions, especially in rapidly growing populations. Preventive measures should focus on reducing high BMI, implementing gender-specific treatments, and addressing regional disparities to mitigate the future burden of KOA.

29 November 2025 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
ZZZiheng Zhu
Ziheng Zhu
CHChuanbing Huang
Chuanbing Huang
JCJunjie Chen
Junjie Chen
LWLei Wan
Lei Wan
CZChuanwei Zhang
Chuanwei Zhang
JWJianing Wang
Jianing Wang
Lactate was traditionally regarded as merely the end product of glycolysis; however, recent discoveries of lactylation have revealed that lactate can also

1 November 2025 in Journal of Inflammation Research
Verified
Journal Article
Open access
PDF file
ZTZhongfu Tang
Zhongfu Tang
LCLili Cheng
Lili Cheng
MLMing Li
Ming Li
JCJunjie Chen
Junjie Chen
CHChuanbing Huang
Chuanbing Huang
Purpose: Osteoarthritis (OA) is a chronic joint disease characterized by articular cartilage damage. Astragaloside IV (AS-IV), a cyclic triterpenoid saponin extracted from Astragalus membranaceus, exhibits antioxidant and cartilage-protective activities. However, its mechanism of action in OA remains unclear. To study the efficacy and mechanism of action of AS-IV in the treatment of OA. Methods: In the SW1353 cell model treated with IL-1β, cell viability was detected by CCK-8, and the ultrastructure of mitochondria was observed by transmission electron microscopy. Multiple methods such as flow cytometry, immunofluorescence, Western blotting, and fluorescent probe method were used to evaluate the effects of AS-IV on chondrocyte ferroptosis and extracellular matrix degradation, and the results were verified by rescue experiments. An OA rat model was established, and multiple methods such as histopathology were used to evaluate the therapeutic effect of AS-IV on OA cartilage injury. Results: In vitro experiments have shown that IL-1β can induce ferroptosis in chondrocytes. Overexpression of p53 promotes ferroptosis in chondrocytes and exacerbates the progression of OA. AS-IV can downregulate the expression of p53 and MMP13, while upregulating the expression of SLC7A11, GPX4, SOX9, Col II, and GSH. Additionally, AS-IV reduces intracellular levels of ROS, MDA, and Fe2+. In an OA rat model, AS-IV significantly reduces the Osteoarthritis Research Society International (OARSI) score and Mankin score, alleviating cartilage damage. Furthermore, AS-IV inhibits extracellular matrix degradation and lipid peroxidation in cartilage tissue. Conclusion: AS-IV inhibits chondrocyte ferroptosis by modulating the p53/SLC7A11/GPX4 axis, thereby alleviating cartilage damage and OA. This suggests that AS-IV has therapeutic potential for OA treatment.

21 August 2025 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
MLMing Li
Ming Li
LPLijun Pang
Lijun Pang
YLYunfei Li
Yunfei Li
JCJunjie Chen
Junjie Chen
SSShuangshuang Shang
Shuangshuang Shang
CHChuanbing Huang
Chuanbing Huang
Purpose: This study aimed to investigate whether Jianpi-Zishen Formula (JPZS) modulates the Treg/Th17 balance in MRL/lpr mice through regulation of DNA methyltransferase 1 (DNMT1)-mediated forkhead box P3 (Foxp3) methylation, and to elucidate its potential mechanism for improving immune homeostasis in systemic lupus erythematosus (SLE).Methods: Forty-eight female MRL/lpr mice were randomized into six groups (n=8/group): JPZS (low/medium/high doses), 5-aza-CdR (DNMT inhibitor), DC_517 (DNMT1 inhibitor), and model control. Eight C57BL/6 mice served as healthy controls. The mice were subjected to the corresponding intervention measures for eight weeks. The impact of JPZS on the disease progression of MRL/lpr mice was evaluated using enzyme-linked immunosorbent assay (ELISA) and serum biochemical parameters. Moreover, immunofluorescence staining and flow cytometry were employed to investigate alterations in the proportions of Tregs and Th17 cells. CD4+ T cells were isolated from the spleen for subsequent investigation, including quantitative real-time PCR, western blotting, and determination of DNA methylation levels. Furthermore, the enzymatic activity of CD4+ T cell-specific DNA methyltransferases was quantified using an EpiQuik DNMT detection kit.Results: JPZS significantly improved the disease development of MRL/lpr mice in a dose-dependent manner. Flow cytometry and immunofluorescence indicated JPZS promoted Treg/Th17 rebalancing. Research has found that Foxp3 is at a high methylation level in CD4+ T cells of the model group, and the transcription level of Foxp3 mRNA is downregulated; JPZS can downregulate Foxp3 methylation levels of CD4+ T cells in the model group. Further research has found that the level of Foxp3 methylation is closely related to Dnmt1 enzyme activity, and JPZS can downregulate Dnmt1 enzyme activity, thereby upregulating the transcription level of Foxp3 mRNA.Conclusion: JPZS may restore Treg/Th17 balance in SLE via DNMT1-regulated Foxp3 demethylation, suggesting an epigenetic mechanism for its immunomodulatory effects.

30 April 2026 in Pharmacological Research
Verified
Journal Article
Open access
ZZZiheng Zhu
Ziheng Zhu
CHChuanbing Huang
Chuanbing Huang
CZChuanwei Zhang
Chuanwei Zhang
JXJiamin Xu
Jiamin Xu
JWJianing Wang
Jianing Wang
Dysregulated programmed cell death (PCD) is a core pathogenic mechanism in rheumatological and immunological disorders, directly causing chronic inflammation, disrupting immune self-tolerance, and leading to irreversible tissue destruction. Classical biological concepts have conventionally characterized PCD modalities as autonomous, linear signaling cascades. However, inflamed tissues from affected patients frequently show activation of multiple cell death markers, and pharmacological interventions that selectively target single PCD pathways have repeatedly yielded disappointing clinical outcomes. These observations indicate extensive molecular crosstalk across the initiation, regulatory integration, and induction of cell death signaling. In this regard, PANoptosis has emerged as a single, synchronized form of inflammatory cell death that combines features of apoptotic, necroptotic, and pyroptotic processes. PANoptosis is not only a coincidental overlap of individual death modalities; it is triggered through a multiprotein signaling complex, the PANoptosome. Through synergistic signaling, the PANoptotic process initiates a cytotoxic cascade that transcends the constraints of conventional linear cell death. Despite its relevance to immune-mediated pathology, a comprehensive, disease-oriented mechanistic pathway for PANoptosis remains underdeveloped in rheumatology and immunology. This review consolidates recent advances to examine the assembly and activation dynamics of representative PANoptosomes across diverse inflammatory microenvironments. In this review, the translational implications of this combined model is examined, highlighting therapeutic strategies that prioritize upstream sensors and regulatory hubs over terminal induction effectors. This review establishes PANoptosis as a pivotal regulatory nexus of inflammatory cell death. It provides a mechanistically unified, translationally oriented pathway to inform next-generation therapeutic development in rheumatic and immune-mediated diseases.

1 October 2025 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
PDF file
ZTZhongfu Tang
Zhongfu Tang
LCLili Cheng
Lili Cheng
MLMing Li
Ming Li
CHChuanbing Huang
Chuanbing Huang
Purpose: Systemic lupus erythematosus (SLE) features immune cell dysfunction, causing immune - complex and inflammatory - factor formation that damages organs. Astragaloside IV (AS-IV), a cyclic triterpene saponin from Astragalus membranaceus, has strong anti-inflammatory and immunomodulatory effects. This study aimed to evaluate AS-IV’s therapeutic potential for SLE and uncover its mechanism. Methods: MRL/lpr mice were divided into MRL/lpr, low - medium - high - dose AS-IV, and Pred groups, with C57BL/6 mice as controls. Renal damage was assessed by histopathology and electron microscopy. Immune parameters were analyzed using ELISA, flow cytometry, immunofluorescence, and immunohistochemistry. Network pharmacology was used to find AS-IV’s SLE targets, and molecular docking was employed to clarify its mechanism, with multiple methods used to measure target expression. Results: AS-IV ameliorated renal pathology by reducing glomerular and vascular wall lesion scores while attenuating immune complex deposition. It significantly decreased podocyte foot process fusion rates, alleviated overall renal damage, and reduced key renal inflammatory cytokines. Systemically, AS-IV reduced spleen index and lowered anti-dsDNA, IgG levels, while restoring complement components C3 and C4, akin to the effects observed in the Pred group. AS-IV notably downregulated the expression of ITGB1, PTK2, p38, IL-4, IL-21, IL-17, and the Th1/Th2 and Th17 ratios, while upregulating the Treg ratio compared to the MRL/lpr group. Molecular docking and Western blot analyses further validated the interaction between AS-IV and the ITGB1/PTK2/p38 axis. Conclusion: AS-IV can modulate the ITGB1/PTK2/p38 axis to suppress immune inflammatory responses, thereby ameliorating SLE progression. These findings suggest the certain therapeutic value of AS-IV in managing SLE.